TY - JOUR
T1 - Basic neuropharmacology of antidepressants relevant to the pharmacotherapy of depression.
AU - Richelson, E.
PY - 1999
Y1 - 1999
N2 - In the past decade, 8 new antidepressants were approved for use in the United States by the US Food and Drug Administration. Six of these have been marketed in the United States since 1992. Two additional drugs marketed outside the United States as antidepressants have been approved in this country for obsessive-compulsive disorder. Together with the conventional antidepressants, the new ones, and the 2 drugs available off-label, the physician can choose from a list of 22 compounds to treat the depressed patient. This article reviews theories about the mechanisms of action of antidepressants and the basic pharmacology of the newer-generation drugs in relation to the older compounds. We hope this information is of use to the clinician in treating acute depression with pharmacologic agents.
AB - In the past decade, 8 new antidepressants were approved for use in the United States by the US Food and Drug Administration. Six of these have been marketed in the United States since 1992. Two additional drugs marketed outside the United States as antidepressants have been approved in this country for obsessive-compulsive disorder. Together with the conventional antidepressants, the new ones, and the 2 drugs available off-label, the physician can choose from a list of 22 compounds to treat the depressed patient. This article reviews theories about the mechanisms of action of antidepressants and the basic pharmacology of the newer-generation drugs in relation to the older compounds. We hope this information is of use to the clinician in treating acute depression with pharmacologic agents.
UR - http://www.scopus.com/inward/record.url?scp=0033251486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033251486&partnerID=8YFLogxK
U2 - 10.1016/S1098-3597(99)90022-4
DO - 10.1016/S1098-3597(99)90022-4
M3 - Article
C2 - 10682175
AN - SCOPUS:0033251486
SN - 1098-3597
VL - 1
SP - 17
EP - 30
JO - Clinical cornerstone
JF - Clinical cornerstone
IS - 4
ER -